Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 01.07.2025
Formycon AG
Press Release // July 1, 2025
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
Partnership marks a landmark step towards global availability of FYB201
Bio Usawa gets exclusive rights to register and commercialize FYB201/BioUcenta™1 in Sub-Saharan Africa
Product launch expected in [ … ]
Fri, 27.06.2025
Formycon AG
Press Release // 27. June 2025
Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Due to strong demand, the offering period for the public offering has been shortened and target volume was increased from initially EUR 50 million to EUR 70 million
Interest [ … ]
Fri, 27.06.2025
Formycon AG
Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE [ … ]
Thu, 26.06.2025
Formycon AG
Press Release // June 26, 2025
Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
Teva's subsidiary Ratiopharm is going to commercialize Fymskina® as a second Formycon ustekinumab biosimilar on a semi-exclusive basis in Germany
Market launch of F [ … ]
Wed, 25.06.2025
Formycon AG
Press Release // June 25, 2025
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
Valorum Biologics, an expert for ophthalmology and oncology biosimilars in the U.S. market, will exclusively commercialize FYB20 [ … ]
Tue, 24.06.2025
Formycon AG
Press Release // June 24, 2025
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
High demand by institutional investors enables early termination of public offering period
Subscription period via the Formycon website is now scheduled to end on 26 June 2025, at 11:59 p.m. CEST
Subscription via Deutsche B [ … ]
Fri, 20.06.2025
Formycon AG
Press Release // June 20, 2025
Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
The subscription period via Deutsche Börse AG's DirectPlace is now open and will close on 30 June 2025 at 12:00 p.m. CEST (subject to early closure)
The unsecured senior bond has a target volume of €50 million and carries a variable i [ … ]
Wed, 18.06.2025
Formycon AG
Press Release // June 18, 2025
Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
Management provides detailed report on financial year 2024 and provides outlook for 2025
Supervisory Board expands to six members; Klaus Röhrig re-elected
Dr. Graham Keith Dixon elected as a new member of the Sup [ … ]
Wed, 18.06.2025
Formycon AG
Press Release // June 18, 2025
Formycon AG: Subscription period for 2025/2029 corporate bond has started
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) announces that the securities prospectus for the newly issued corporate bond 2025/2029 (ISIN NO0013586024 / WKN A4DFJH) has been approved by the Luxembourg finan [ … ]
Tue, 17.06.2025
Formycon AG
Press Release // June 17, 2025
Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
Unsecured bond 2025/2029 with a target volume of EUR 50 million and variable interest rate
Proceeds will support the targeted development of biosimilar product portfolio and the execution of the next grow [ … ]